luciferin 6’benzyl ether (luciferin-be)

Need public description.

Compound information managed by NaPDI


None listed

None listed

None listed

ID Subject of Study Study Name Name Type Overall Effect Enzymes Transporters Object Object Metabolite Precipitant
NPDI-M8nR1A Kratom (Mitragyna speciosa) Inhibitory effect of mitragynine on human cytochrome P450 enzyme activities Enzyme kinetics of CYP3A4 In Vitro Enzyme Kinetics positive — In Vitro Detectable Kinetic Metabolism
  • CYP3A4
luciferin 6’benzyl ether (luciferin-be) luciferin
NPDI-d-iKog Kratom (Mitragyna speciosa) Inhibitory effect of mitragynine on human cytochrome P450 enzyme activities POS. CONTROL: Inhibition of CYP3A4 by ketoconazole In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP3A4
luciferin 6’benzyl ether (luciferin-be) luciferin ketoconazole
NPDI-ypADxQ Kratom (Mitragyna speciosa) Inhibitory effect of mitragynine on human cytochrome P450 enzyme activities No inhibition of CYP3A4 by mitragynine In Vitro Enzyme Inhibition negative — In Vitro Enzyme Negligible Inhibition
  • CYP3A4
luciferin 6’benzyl ether (luciferin-be) luciferin mitragynine
NPDI-79TG7g Kratom (Mitragyna speciosa) Evaluation of selected Malaysian medicinal plants on phase I drug metabolizing enzymes, CYP2C9, CYP2D6 and CYP3A4 activities in vitro POS. CONTROL: Inhibition of CYP3A4 by ketoconazole In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP3A4
luciferin 6’benzyl ether (luciferin-be) luciferin ketoconazole
NPDI-Df2Xyw Kratom (Mitragyna speciosa) Evaluation of selected Malaysian medicinal plants on phase I drug metabolizing enzymes, CYP2C9, CYP2D6 and CYP3A4 activities in vitro Negligible inhibition of CYP3A4 by M. speciosa methanolic extract In Vitro Enzyme Inhibition negative — In Vitro Enzyme Negligible Inhibition
  • CYP3A4
luciferin 6’benzyl ether (luciferin-be) luciferin methanolic extract of kratom